An open-label companion study of zilovertamab plus ibrutinib for patients who have progressive disease during the initial four months of ibrutinib monotherapy from Study ZILO-301
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Zilovertamab (Primary) ; Ibrutinib
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms ZILO-302
- 14 Jul 2022 According to an Oncternal Therapeutics media release, company entered into a clinical trial collaboration with Pharmacyclics, Under the terms of the collaboration, the supply of ibrutinib will support this study.
- 11 Jan 2022 New trial record